VACCINE FOR THE PREVENTION OF ANAPLASMA PHAGOCYTOPHILUM INFECTION (RICKETTSIALES: ANAPLASMATACEAE) (Machine-translation by Google Translate, not legally binding)
Vaccine for the prevention of Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae) infection. The invention refers to a chimeric protein that contains protective peptides against infection by the pathogen Anaplasma phagocytophilum. The chimeric antigen comprises the epitopes of the Anaplasma p...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | De la Fuente García, José de Jesús Contreras Rojo, Marinela |
| description | Vaccine for the prevention of Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae) infection. The invention refers to a chimeric protein that contains protective peptides against infection by the pathogen Anaplasma phagocytophilum. The chimeric antigen comprises the epitopes of the Anaplasma phagocytophilum MSP4 protein, specifically the chimeric antigen of the present invention comprises 4 amino acid subsequences of MSP4. The chimeric antigen of the present invention produced a greater immunological response compared to the administration of the complete MSP4 protein and with a control peptide when this was administered to animals susceptible to Anaplasma phagocytophilum infections. So that the chimeric antigen of the present invention has an advantage for the prevention and/or treatment of infections caused by bacteria belonging to the Anaplasmataceae family. (Machine-translation by Google Translate, not legally binding)
Vacuna para la prevención de la infección de Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae). La invención hace referencia a una proteína quimérico que contiene péptidos protectores frente a la infección por el patógeno Anaplasma phagocytophilum. El antígeno quimérico comprende los epítopos de la proteína MSP4 Anaplasma phagocytophilum, específicamente el antígeno quimérico de la presente invención comprende 4 subsecuencias de aminoácidos de MSP4. El antígeno quimérico de la presente invención produjo una respuesta inmunológica mayor en comparación con la administración de la proteína completa MSP4 y con un péptido control cuando este se administró a animales susceptibles de padecer infecciones por Anaplasma phagocytophilum. De manera que el antígeno quimérico de la presente invención presenta una ventaja para la prevención y/o tratamiento de infecciones causadas por bacterias pertenecientes a la familia Anaplasmataceae. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ES2967368A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ES2967368A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ES2967368A13</originalsourceid><addsrcrecordid>eNqNi8FqwkAUAHPpQaz_8I4KeqgBW709lpdkabIbklXwJKs-08CyG5pc8jn-qVCEXj0NDDOT6H5AIaQiSHQFJiMoKzqQMlIr0AmgwjLHukAoM0y1OBpdZjLfFyBVQuIvm1dSfJMxtcSc6t3_Y1AQ0gLmhb38tJ5Xw6_1vbNDGzycR0hDaByDeVpegg8DOG6scyOcW39tfbN4j95u1vU8e3IaQUJGZCvuwon7zl7Y83Cier3dfMabL_yIX0geBKNK7w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>VACCINE FOR THE PREVENTION OF ANAPLASMA PHAGOCYTOPHILUM INFECTION (RICKETTSIALES: ANAPLASMATACEAE) (Machine-translation by Google Translate, not legally binding)</title><source>esp@cenet</source><creator>De la Fuente García, José de Jesús ; Contreras Rojo, Marinela</creator><creatorcontrib>De la Fuente García, José de Jesús ; Contreras Rojo, Marinela</creatorcontrib><description>Vaccine for the prevention of Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae) infection. The invention refers to a chimeric protein that contains protective peptides against infection by the pathogen Anaplasma phagocytophilum. The chimeric antigen comprises the epitopes of the Anaplasma phagocytophilum MSP4 protein, specifically the chimeric antigen of the present invention comprises 4 amino acid subsequences of MSP4. The chimeric antigen of the present invention produced a greater immunological response compared to the administration of the complete MSP4 protein and with a control peptide when this was administered to animals susceptible to Anaplasma phagocytophilum infections. So that the chimeric antigen of the present invention has an advantage for the prevention and/or treatment of infections caused by bacteria belonging to the Anaplasmataceae family. (Machine-translation by Google Translate, not legally binding)
Vacuna para la prevención de la infección de Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae). La invención hace referencia a una proteína quimérico que contiene péptidos protectores frente a la infección por el patógeno Anaplasma phagocytophilum. El antígeno quimérico comprende los epítopos de la proteína MSP4 Anaplasma phagocytophilum, específicamente el antígeno quimérico de la presente invención comprende 4 subsecuencias de aminoácidos de MSP4. El antígeno quimérico de la presente invención produjo una respuesta inmunológica mayor en comparación con la administración de la proteína completa MSP4 y con un péptido control cuando este se administró a animales susceptibles de padecer infecciones por Anaplasma phagocytophilum. De manera que el antígeno quimérico de la presente invención presenta una ventaja para la prevención y/o tratamiento de infecciones causadas por bacterias pertenecientes a la familia Anaplasmataceae.</description><language>eng ; spa</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240429&DB=EPODOC&CC=ES&NR=2967368A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25551,76302</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240429&DB=EPODOC&CC=ES&NR=2967368A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>De la Fuente García, José de Jesús</creatorcontrib><creatorcontrib>Contreras Rojo, Marinela</creatorcontrib><title>VACCINE FOR THE PREVENTION OF ANAPLASMA PHAGOCYTOPHILUM INFECTION (RICKETTSIALES: ANAPLASMATACEAE) (Machine-translation by Google Translate, not legally binding)</title><description>Vaccine for the prevention of Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae) infection. The invention refers to a chimeric protein that contains protective peptides against infection by the pathogen Anaplasma phagocytophilum. The chimeric antigen comprises the epitopes of the Anaplasma phagocytophilum MSP4 protein, specifically the chimeric antigen of the present invention comprises 4 amino acid subsequences of MSP4. The chimeric antigen of the present invention produced a greater immunological response compared to the administration of the complete MSP4 protein and with a control peptide when this was administered to animals susceptible to Anaplasma phagocytophilum infections. So that the chimeric antigen of the present invention has an advantage for the prevention and/or treatment of infections caused by bacteria belonging to the Anaplasmataceae family. (Machine-translation by Google Translate, not legally binding)
Vacuna para la prevención de la infección de Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae). La invención hace referencia a una proteína quimérico que contiene péptidos protectores frente a la infección por el patógeno Anaplasma phagocytophilum. El antígeno quimérico comprende los epítopos de la proteína MSP4 Anaplasma phagocytophilum, específicamente el antígeno quimérico de la presente invención comprende 4 subsecuencias de aminoácidos de MSP4. El antígeno quimérico de la presente invención produjo una respuesta inmunológica mayor en comparación con la administración de la proteína completa MSP4 y con un péptido control cuando este se administró a animales susceptibles de padecer infecciones por Anaplasma phagocytophilum. De manera que el antígeno quimérico de la presente invención presenta una ventaja para la prevención y/o tratamiento de infecciones causadas por bacterias pertenecientes a la familia Anaplasmataceae.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi8FqwkAUAHPpQaz_8I4KeqgBW709lpdkabIbklXwJKs-08CyG5pc8jn-qVCEXj0NDDOT6H5AIaQiSHQFJiMoKzqQMlIr0AmgwjLHukAoM0y1OBpdZjLfFyBVQuIvm1dSfJMxtcSc6t3_Y1AQ0gLmhb38tJ5Xw6_1vbNDGzycR0hDaByDeVpegg8DOG6scyOcW39tfbN4j95u1vU8e3IaQUJGZCvuwon7zl7Y83Cier3dfMabL_yIX0geBKNK7w</recordid><startdate>20240429</startdate><enddate>20240429</enddate><creator>De la Fuente García, José de Jesús</creator><creator>Contreras Rojo, Marinela</creator><scope>EVB</scope></search><sort><creationdate>20240429</creationdate><title>VACCINE FOR THE PREVENTION OF ANAPLASMA PHAGOCYTOPHILUM INFECTION (RICKETTSIALES: ANAPLASMATACEAE) (Machine-translation by Google Translate, not legally binding)</title><author>De la Fuente García, José de Jesús ; Contreras Rojo, Marinela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ES2967368A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; spa</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>De la Fuente García, José de Jesús</creatorcontrib><creatorcontrib>Contreras Rojo, Marinela</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>De la Fuente García, José de Jesús</au><au>Contreras Rojo, Marinela</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>VACCINE FOR THE PREVENTION OF ANAPLASMA PHAGOCYTOPHILUM INFECTION (RICKETTSIALES: ANAPLASMATACEAE) (Machine-translation by Google Translate, not legally binding)</title><date>2024-04-29</date><risdate>2024</risdate><abstract>Vaccine for the prevention of Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae) infection. The invention refers to a chimeric protein that contains protective peptides against infection by the pathogen Anaplasma phagocytophilum. The chimeric antigen comprises the epitopes of the Anaplasma phagocytophilum MSP4 protein, specifically the chimeric antigen of the present invention comprises 4 amino acid subsequences of MSP4. The chimeric antigen of the present invention produced a greater immunological response compared to the administration of the complete MSP4 protein and with a control peptide when this was administered to animals susceptible to Anaplasma phagocytophilum infections. So that the chimeric antigen of the present invention has an advantage for the prevention and/or treatment of infections caused by bacteria belonging to the Anaplasmataceae family. (Machine-translation by Google Translate, not legally binding)
Vacuna para la prevención de la infección de Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae). La invención hace referencia a una proteína quimérico que contiene péptidos protectores frente a la infección por el patógeno Anaplasma phagocytophilum. El antígeno quimérico comprende los epítopos de la proteína MSP4 Anaplasma phagocytophilum, específicamente el antígeno quimérico de la presente invención comprende 4 subsecuencias de aminoácidos de MSP4. El antígeno quimérico de la presente invención produjo una respuesta inmunológica mayor en comparación con la administración de la proteína completa MSP4 y con un péptido control cuando este se administró a animales susceptibles de padecer infecciones por Anaplasma phagocytophilum. De manera que el antígeno quimérico de la presente invención presenta una ventaja para la prevención y/o tratamiento de infecciones causadas por bacterias pertenecientes a la familia Anaplasmataceae.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; spa |
| recordid | cdi_epo_espacenet_ES2967368A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | VACCINE FOR THE PREVENTION OF ANAPLASMA PHAGOCYTOPHILUM INFECTION (RICKETTSIALES: ANAPLASMATACEAE) (Machine-translation by Google Translate, not legally binding) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T02%3A41%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=De%20la%20Fuente%20Garc%C3%ADa,%20Jos%C3%A9%20de%20Jes%C3%BAs&rft.date=2024-04-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EES2967368A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |